PpProf. Peptide
Back to Peptide Library

KLOW

Skin Health & Anti-AgingResearch-GradeCombination Blend

Last reviewed: May 15, 2026

Also Known As: KPV-GHK-Cu-BPC-157-TB-500 Blend, KLOW Blend, KLOW Stack

Peptide Class: Recovery & Skin Repair Blend (4-component)

Regulatory Status: Research-grade only (no clinical trial evidence on combination)

What is KLOW?

KLOW is a research-grade 4-component peptide blend combining BPC-157, TB-500, GHK-Cu, and KPV in a single injection. It extends the 3-component GLOW blend by adding KPV, a tripeptide derived from α-melanocyte-stimulating hormone (α-MSH) that suppresses NF-κB-mediated inflammation. The result is the most comprehensive of the BPC/TB-based recovery blends: tissue repair from BPC-157 + TB-500, skin remodeling from GHK-Cu, and inflammation control from KPV — on a calmer tissue background.

Reported benefits:

  • Soft-tissue injury work with persistent inflammatory component (tendon, ligament, muscle)
  • Post-procedure aesthetic recovery (microneedling, laser, surgery)
  • Reactive or chronically inflamed skin where pure GLOW would aggravate
  • Comprehensive collagen + extracellular matrix remodeling on top of inflammation suppression
  • Gut and mucosal barrier work (mechanistic — based on KPV and BPC-157 component literature)
  • Single-injection convenience vs four separate peptide protocols

Common research dose: 0.1 mL (10 units on a U-100 insulin syringe) once daily subcutaneously from an 80 mg vial reconstituted with 2 mL bacteriostatic water — delivering ~2.5 mg GHK-Cu + 0.5 mg of each of BPC-157, TB-500, and KPV per dose. Standard cycle 8–12 weeks active, 4-week break.

Where to buy: KLOW is sold by specialty research peptide vendors as a compounded blend, typically as an 80 mg vial. None of the four components are FDA-approved as injectables. See Verified Discount Codes → for current options.

How does KLOW work?

KLOW combines four research peptides that each target a different stage of tissue repair. BPC-157 and TB-500 act like the demolition and framing crew — they rebuild blood vessels and move repair cells into position. GHK-Cu is the finishing crew, laying down new collagen and signaling skin and connective tissue to remodel. KPV (a tripeptide from the same family as α-MSH, the hormone behind pigmentation) acts as a fire marshal — it keeps inflammation from drowning out the rebuild signals.

  1. BPC-157 — Vascular Repair [2]. BPC-157 (Body Protection Compound) activates the nitric oxide / VEGFR2 / FAK-paxillin axis to drive angiogenesis and endothelial protection. It rebuilds the blood supply that healing tissue needs, and stabilizes vascular networks at injury sites.
  2. TB-500 — Cellular Migration [3]. TB-500, the active fragment of thymosin β4, sequesters G-actin to enable cytoskeletal remodeling. The functional effect is rapid migration of fibroblasts and endothelial progenitor cells to injury sites, plus the anti-fibrotic Ac-SDKP fragment that biases healing toward functional tissue rather than scar.
  3. GHK-Cu — Collagen and Gene Modulation [1]. GHK-Cu (copper tripeptide) shuttles copper into cells and modulates expression of more than 4,000 human genes associated with skin remodeling, antioxidant defense, and stem-cell support. Its strongest signals are in dermal collagen synthesis, lysyl-oxidase cross-linking, and clearance of damaged extracellular matrix.
  4. KPV — Inflammation Control [4][5]. KPV (lysine–proline–valine) is the C-terminal tripeptide of α-MSH. It enters cells via the PepT1 nutrient transporter and inhibits NF-κB nuclear translocation — blocking transcription of TNF-α, IL-6, IL-1β, and adhesion molecules. Unlike α-MSH, KPV does not engage melanocortin receptors, so it produces anti-inflammatory effects without pigmentation, appetite, or immunosuppression side effects.
  5. Composite effect — Repair on a calm background. The three regenerative components (BPC-157, TB-500, GHK-Cu) act on a tissue environment that KPV is actively de-inflaming. In principle this allows the rebuilding signals to reach their cellular targets without being attenuated by chronic NF-κB activation. The synergy is mechanistic — there is no controlled trial of the four-component blend.

What is KLOW used for?

Researchers use KLOW where the goal is broad tissue and skin recovery on top of a controlled inflammatory environment. Where Wolverine Stack is for pure injury work and GLOW adds skin quality, KLOW adds the inflammation-control layer that's useful when the tissue or skin in question is reactive — irritated, post-procedural, autoimmune-adjacent, or chronically inflamed. None of the research below is from controlled trials of the KLOW blend itself; it comes from each component's independent literature.

  1. Reactive Skin and Post-Procedure Recovery — Inflammation control from KPV plus collagen remodeling from GHK-Cu plus angiogenic support from BPC-157 makes KLOW the most-cited blend for post-microneedling, post-laser, and post-surgical aesthetic recovery use cases in research-community discussions.
  2. Soft-Tissue Injury With Inflammatory Component — Tendon, ligament, or muscle injuries with persistent inflammation. BPC-157 and TB-500 supply the repair signals; KPV dampens NF-κB to prevent inflammatory drag on healing.
  3. Gut and Mucosal Barrier — KPV has independent preclinical evidence in inflammatory bowel models, where it suppresses NF-κB and protects mucosal barriers. BPC-157 has been studied separately for gastrointestinal protection. The combined application is mechanistically rational but not directly studied as KLOW.
  4. Chronic Inflammatory Skin Conditions — Atopic and irritant dermatitis models have shown anti-inflammatory effects from KPV alone. The addition of GHK-Cu's barrier-remodeling activity is the rationale for KLOW use in such applications.
  5. Hair Follicle Stimulation — GHK-Cu's dominant contribution; BPC-157's angiogenic effect on follicular blood supply supports the same outcome. Effects typically emerge 60–90 days into protocol.

How long does KLOW take to work?

KLOW effects build progressively across an 8–12 week cycle. Visible improvements in skin texture and tone usually appear by week 3–4, similar to topical retinoids on a faster timeline. Fine-line softening and inflammatory-skin calming follow at weeks 4–6. Deeper structural changes — scar remodeling, sustained tendon or ligament repair, collagen-driven firmness — accumulate through weeks 8–12.

Tissue repair signals from BPC-157 and TB-500 act fast: angiogenesis markers can shift in days. KPV's anti-inflammatory effect is similarly rapid — NF-κB inhibition begins after the first dose. GHK-Cu's gene-modulating effects accumulate more slowly because they require ongoing transcription cycles, which is why structural skin and connective-tissue improvements typically lag the inflammation calming by several weeks. A standard protocol runs 8–12 weeks active with a 4-week break, then optional re-cycle.

How is KLOW dosed?

KLOW is administered as a once-daily subcutaneous injection. Because the blend is research-grade and there are no clinical trial protocols, vendor and community protocols converge on the following defaults — derived from anchoring to a target dose of the most-studied component (BPC-157 for injury work, GHK-Cu for skin work) and letting the fixed ratio determine the rest.

Standard research protocol (80 mg vial):

  1. Injury-anchored. Reconstitute 80 mg vial with 2 mL bacteriostatic water. Inject 0.1 mL (10 units on a U-100 insulin syringe) once daily subcutaneously. Each dose delivers ~2.5 mg GHK-Cu + 0.5 mg BPC-157 + 0.5 mg TB-500 + 0.5 mg KPV.
  2. Skincare-anchored. Reconstitute 80 mg vial with 2.5 mL bacteriostatic water. Inject 0.1 mL once daily — delivering ~2 mg GHK-Cu + 0.4 mg of each of BPC-157, TB-500, and KPV.
  3. Cycle length. 8–12 weeks active, then 4–8 weeks off (or step down to a 2–3× weekly maintenance dose).
  4. Site rotation. Alternate abdomen, thigh, and upper arm. Inject as close to the injury site as practical for soft-tissue injury work.
  5. Timing. Bedtime is the common default, at least 2 hours after the last meal.

Pre-blended formulations (research-grade vials)

Standard SKU. The 80 mg KLOW vial is the dominant SKU across specialty peptide vendors. The vial label shows the total combined milligrams of all four components — 80 mg in this case — at a fixed 50 / 10 / 10 / 10 mg breakdown.

Component breakdown. 50 mg GHK-Cu (62.5%) + 10 mg BPC-157 (12.5%) + 10 mg TB-500 (12.5%) + 10 mg KPV (12.5%). The ratio is locked at this 5:1:1:1 split in pre-blended product; researchers wanting a different ratio (for example, equal GHK-Cu and BPC-157 for an injury-dominant protocol) need to buy the four components separately.

Reconstitution math. Treat the combined 80 mg as the vial size in the dosing calculator. Because the ratio is fixed, every drawn unit contains the same 5:1:1:1 mix. A 2 mL reconstitution yields 40 mg/mL total — and any drawn volume delivers 62.5% of that total as GHK-Cu and 12.5% each as BPC-157, TB-500, and KPV.

Ratio variants. Some vendors offer different SKUs — 40 mg, 50 mg, or 100 mg total — with the same 5:1:1:1 component ratio. Verify the per-component breakdown on the vendor's Certificate of Analysis before scaling a protocol.

KLOW is not FDA-approved. Dosing is community-derived from individual component research — there are no approved retail dosing standards for the blend.

Need to calculate your dose? Convert mg to syringe units and plan reconstitution with the dosage calculator →.

How is KLOW administered?

KLOW is administered by subcutaneous injection, the same route used for insulin and most research peptides — under the skin, not into muscle. A small insulin syringe makes this straightforward. The blend is once-daily, typically at bedtime, with site rotation to spread injection-site reactions across abdomen, thigh, and upper arm.

  1. Route. Subcutaneous injection. Common sites are the abdomen (avoiding a 2-inch radius around the navel), upper outer thighs, and back of the upper arms.
  2. Time of day. Bedtime is the standard default — gives the peptides an undisturbed window during early-night tissue repair cycles. Any consistent time works.
  3. With or without food. Either is fine. KLOW components do not interact with food absorption.
  4. Site rotation. Alternate sites each injection. Stay at least 1 inch from previous injection sites — mild injection-site reactions are the most commonly reported side effect.
  5. Missed dose. Resume on the next scheduled day. Do not double-dose to compensate for a missed daily injection.
  6. Reconstitution. Use bacteriostatic water for injection (BAC water) at the volume specified by the dosing calculator. Swirl gently — do not shake — to avoid damaging the peptides.
  7. Local injection for soft-tissue work. For tendon, ligament, or post-procedure recovery applications, researchers often inject within 1–2 inches of the affected area rather than at a distant rotation site.

What does KLOW stack well with?

KLOW is designed to be a standalone blend — it already contains four peptides covering tissue repair, skin remodeling, and inflammation control. Most useful additions are non-peptide (resistance training, protein, topical skin actives). The thing to avoid is double-dosing any of the four components by stacking with standalone BPC-157, TB-500, GHK-Cu, or KPV — or with the sibling blends GLOW or Wolverine Stack, which overlap.

  1. Resistance training + 1.2–1.6 g/kg protein. Standard anabolic-context pairing for any tissue-repair or recovery use case. The strongest non-peptide multiplier on KLOW's repair signal.
  2. Topical GHK-Cu serum. Layered skin effect — injectable KLOW for systemic GHK-Cu gene expression plus topical for local skin concentration. Avoid applying high-concentration vitamin C topical at the same time as topical GHK-Cu.
  3. Topical retinoids. Compatible with KLOW. The collagen-stimulating effects are additive.
  4. Avoid: full-dose standalone components. KLOW already contains BPC-157, TB-500, GHK-Cu, and KPV at meaningful doses. Adding standalone protocols of any of these doubles the dose without independent benefit.
  5. Avoid: GLOW and Wolverine Stack. Both overlap with KLOW's components. See GLOW for the 3-component skin/recovery version (no KPV) or Wolverine Stack for the 2-component pure-injury version (BPC-157 + TB-500 only).

What are the side effects of KLOW?

Most reported KLOW side effects are mild and local — injection-site reactions, transient fatigue, mild gastrointestinal changes — and consistent with what individual components produce in their own research. There is no controlled safety trial of the four-peptide blend, so all severity estimates are extrapolated from each component's literature plus user reports. The GHK-Cu copper-allergy risk and the BPC-157 / TB-500 anti-doping prohibitions are the most material concerns to flag.

Common (most users)

  1. Injection site reactions. Mild redness, irritation, or transient pinkness at the injection site. The most commonly reported KLOW side effect.
  2. Transient fatigue. Mild post-injection tiredness, typically resolving overnight.
  3. Mild GI changes. Mild loose stool or appetite changes — reflects BPC-157 and KPV activity on gut signaling.

Less common (moderate)

  1. Headache. Typically mild, common after first few doses during the early cycle.
  2. Lightheadedness. Usually transient and dose-related; often resolved by smaller volumes or split dosing.
  3. Skin pigmentation drift. Theoretical concern with GHK-Cu and α-MSH-derived peptides; KPV is not believed to bind melanocortin receptors, but pigmentation should be watched, particularly in users with reactive skin.

Serious (rare)

  1. Copper allergy reactions. From the GHK-Cu component — hives, swelling, or systemic allergic response. Discontinue immediately.
  2. Anti-doping prohibitions. BPC-157 and TB-500 are on the WADA prohibited list (Section S0). Tested athletes should not use any KLOW formulation.
  3. Theoretical component-level concerns apply. Each component carries its own (mostly preclinical) safety considerations — see the individual component pages.

KLOW combines four peptides with no FDA approval as injectables. Compounded preparations vary widely in quality — third-party HPLC testing of each component is essential. The combined safety profile of the four-peptide blend has not been formally studied.

Does KLOW interact with other drugs?

KLOW has no well-documented systemic drug interactions. Each component's individual interaction profile applies — BPC-157 and TB-500's angiogenic activity creates a theoretical concern for users on anticoagulants, and GHK-Cu's copper component creates theoretical concern for users on copper-modifying agents or vitamin C megadosing. None of these have shown up as clinically meaningful in the component literature.

  1. Anticoagulants (warfarin, DOACs). Theoretical concern from BPC-157 and TB-500 angiogenic activity. No documented clinical events.
  2. High-concentration topical vitamin C. Apply at separate times from topical GHK-Cu products if combining injectable KLOW with topical regimens.
  3. Copper-modifying agents. Theoretical concern from the GHK-Cu component for users on zinc supplementation at high doses or on copper-chelating therapy.
  4. Component-level interactions. Cross-reference individual component pages — BPC-157, TB-500, GHK-Cu, KPV — for full per-component interaction profiles.
  5. Alcohol. No specific interaction documented. General hydration concerns apply for any peptide-injection protocol.

How should KLOW be stored?

  1. Lyophilized (powder) form: -20°C long-term, 2–8°C short-term (refrigerated).
  2. Reconstituted solution: 2–8°C, use within 30 days.
  3. Reconstitution: bacteriostatic water for injection (BAC water). Swirl gently — do not shake.
  4. Do not freeze the reconstituted solution. Freezing damages the peptides and renders them inactive.
  5. Protect from light — store in the original container or amber vial.
  6. Discard if the solution is cloudy, discolored, or contains particles.

What are the limitations of KLOW research?

KLOW is a community-derived blend — no controlled trial has tested the four-peptide combination as a single product. All efficacy and safety claims rest on each component's independent literature plus mechanistic reasoning about complementarity. The regulatory status is the strictest concern: none of the four components are FDA-approved as injectables, and quality varies dramatically across vendors.

KLOW is NOT FDA-approved. Each individual component has its own regulatory status — GHK-Cu (FDA-restricted as a compounded injectable since 2023), BPC-157 (Category 2 bulk drug substance, research-only), TB-500 (research-only), KPV (research-only, no approved injectable form). The four-peptide blend has no clinical trial evidence as a combination.

Compounded KLOW preparations are sold as “research peptides.” Quality varies dramatically by source. Third-party HPLC testing of each component is strongly recommended — both for purity and to verify the labeled 50 / 10 / 10 / 10 mg breakdown.

Synergy claims are mechanistic, not empirical. The proposition that KPV-mediated NF-κB suppression amplifies the regenerative signal from BPC-157, TB-500, and GHK-Cu is biologically plausible but has not been tested as a combination versus its components or versus a 3-peptide GLOW formulation.

Anti-doping: BPC-157 and TB-500 are on the WADA prohibited list (Section S0). GHK-Cu and KPV are not currently listed as prohibited substances. Tested athletes should not use any KLOW formulation that includes BPC-157 or TB-500 — which is all of them.

KLOW FAQ

What is KLOW?

KLOW is a research-grade 4-component peptide blend: BPC-157 + TB-500 + GHK-Cu + KPV. It extends the GLOW blend (BPC-157 + TB-500 + GHK-Cu) by adding KPV, a tripeptide derived from α-melanocyte-stimulating hormone (α-MSH). The standard vendor SKU is an 80 mg vial: 50 mg GHK-Cu + 10 mg BPC-157 + 10 mg TB-500 + 10 mg KPV.

How does KLOW differ from GLOW?

KLOW is GLOW plus KPV. GLOW already covers tissue repair (BPC-157 + TB-500) and skin/collagen remodeling (GHK-Cu). KLOW adds an anti-inflammatory layer through KPV, which inhibits NF-κB and dampens the inflammatory environment that can interfere with the rebuilding signals from the other three components. Researchers typically step up: Wolverine Stack (pure injury recovery) → GLOW (recovery + skin) → KLOW (recovery + skin + inflammation control).

How does KPV work in the blend?

KPV is a lysine–proline–valine tripeptide derived from the C-terminal end of α-MSH. It enters cells via the PepT1 nutrient transporter and inhibits the NF-κB inflammatory signaling pathway directly, without binding melanocortin receptors. The net effect is suppressed production of pro-inflammatory cytokines (TNF-α, IL-6, IL-1β) without the skin darkening, appetite changes, or immunosuppression seen with α-MSH itself. In a multi-component blend, this is meant to pre-empt the inflammatory cascade so the regenerative signals from BPC-157, TB-500, and GHK-Cu can act on a calmer tissue environment.

Is KLOW FDA-approved?

No. None of the four components are FDA-approved as injectables. GHK-Cu has been FDA-restricted for compounded injectable preparation since 2023; BPC-157 sits on the FDA Category 2 bulk drug substance list; TB-500 and KPV have no FDA approval. There are no clinical trials of the KLOW combination — synergy claims rest on the mechanistic complementarity of each component, not on a comparative trial of the blend.

What's a typical KLOW dose?

Vendor protocols converge on 0.1 mL (10 units on a U-100 insulin syringe) once daily subcutaneously for the standard 80 mg vial reconstituted with 2 mL bacteriostatic water. That delivers approximately 4 mg total per dose: 2.5 mg GHK-Cu + 0.5 mg BPC-157 + 0.5 mg TB-500 + 0.5 mg KPV. Skincare-focused protocols sometimes use 2.5 mL BAC water (anchored to a 2 mg GHK-Cu target dose); injury-focused protocols anchor to 0.5 mg BPC-157 and use 2 mL. Standard cycle: 8–12 weeks active, then a 4-week break.

Where can I buy KLOW?

KLOW is sold as a pre-blended 80 mg vial by specialty research peptide vendors. Quality varies dramatically by source — third-party HPLC testing of each component is essential. PP maintains a list of vetted vendors with verified discount codes — see Verified Discount Codes →.

Can KLOW be stacked with other peptides?

KLOW already contains the full BPC-157 + TB-500 + GHK-Cu + KPV set, so stacking with standalone versions of any of those four components risks double-dosing. The most common additions are resistance training and adequate protein for anabolic context, and topical GHK-Cu serum for layered skin effect. Avoid stacking with full-dose GLOW or Wolverine Stack — they overlap with KLOW's components.

Is the blend's safety profile established?

Not as a combination. Each component has its own preclinical safety record — generally favorable across short-duration animal and limited human research — but there are no controlled trials of the four-peptide blend. Most observed side effects in user reports are mild (injection site reactions, transient fatigue, mild GI changes) and consistent with what individual components produce.

References

  1. Pickart L, Margolina A. Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data. Int J Mol Sci. 2018;19(7):1987. https://pmc.ncbi.nlm.nih.gov/articles/PMC6073405/
  2. Sikiric P, Hahm KB, Blagaic AB, et al. Stable Gastric Pentadecapeptide BPC 157: Robust Vascular Therapy in Ischemia/Reperfusion Injury. Front Pharmacol. 2018;9:1383. https://pmc.ncbi.nlm.nih.gov/articles/PMC5333585/
  3. Goldstein AL, Hannappel E, Sosne G, Kleinman HK. Thymosin β4: A Multi-Functional Regenerative Peptide. Expert Opin Biol Ther. 2012;12(1):37-51. https://pubmed.ncbi.nlm.nih.gov/22074294/
  4. Brzoska T, Luger TA, Maaser C, Abels C, Böhm M. α-MSH-Related Peptides: A New Class of Anti-Inflammatory and Immunomodulating Drugs. Endocr Rev. 2008;29(5):581-602. https://pmc.ncbi.nlm.nih.gov/articles/PMC2095288/
  5. Wadhwani SD, Catania A, Lipton JM, et al. Immobilized α-melanocyte stimulating hormone 10–13 (GKPV) inhibits tumor necrosis factor-α stimulated NF-κB activity. Neuropeptides. 2006. https://www.sciencedirect.com/science/article/abs/pii/S0196978105004560
  6. Goldstein AL, Hannappel E, Kleinman HK. Thymosin β4: Actin Sequestering Protein Moonlights to Repair Injured Tissues. Trends Mol Med. 2005;11(9):421-9. https://pubmed.ncbi.nlm.nih.gov/16099219/

Published Studies

KLOW has no controlled trial as a combination. The studies below are the key peer-reviewed sources for each individual component's mechanism — the empirical basis for the four-peptide blend's mechanistic rationale.

International Journal of Molecular Sciences · 2018Open Access
Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data →

Pickart L, Margolina A

Comprehensive review establishing GHK-Cu's gene-modulating action across thousands of human genes — over 4,000 affected, including reset of expression patterns associated with skin aging, wound healing, and tissue regeneration. The paper synthesizes decades of work demonstrating GHK-Cu's roles in collagen and elastin synthesis, copper transport, anti-inflammatory signaling, and stem-cell support. It is the foundational reference for GHK-Cu's contribution to combination blends like KLOW.

Frontiers in Pharmacology · 2018Open Access
Stable Gastric Pentadecapeptide BPC 157: Robust Vascular Therapy in Ischemia/Reperfusion Injury →

Sikiric P, Hahm KB, Blagaic AB, et al.

Reviews BPC-157's mechanism centered on the nitric oxide / VEGFR2 / FAK-paxillin axis — driving angiogenesis, endothelial protection, and rapid vascular network reconstruction at injury sites. BPC-157's vascular action is the primary mechanism by which it complements TB-500's cellular-migration effect in tissue-repair blends like Wolverine, GLOW, and KLOW.

Expert Opinion on Biological Therapy · 2012Paywalled
Thymosin β4: a Multi-Functional Regenerative Peptide →

Goldstein AL, Hannappel E, Sosne G, Kleinman HK

Reviews the parent peptide of TB-500 (the active fragment of thymosin β4). Mechanism centers on G-actin sequestration to enable cytoskeletal remodeling, cellular migration of repair cells (fibroblasts, endothelial progenitors) to injury sites, and the anti-fibrotic Ac-SDKP fragment that biases healing toward functional tissue rather than scar. In KLOW, TB-500 supplies the cellular-migration arm of the repair triad.

Endocrine Reviews · 2008Open Access
α-MSH-Related Peptides: A New Class of Anti-Inflammatory and Immunomodulating Drugs →

Brzoska T, Luger TA, Maaser C, Abels C, Böhm M

Comprehensive review of α-MSH and its C-terminal tripeptide KPV as anti-inflammatory agents. Establishes that most of α-MSH's anti-inflammatory activity is recapitulated by KPV alone — including suppression of pro-inflammatory cytokines, inhibition of NF-κB nuclear translocation, and modulation of adhesion molecule expression — but without the melanocortin-receptor-mediated effects (pigmentation, appetite, immunosuppression) of the full hormone. This decoupling is the rationale for using KPV rather than α-MSH itself in blends like KLOW.

Neuropeptides / ScienceDirect · 2006Paywalled
α-MSH (10–13) Inhibits TNF-α-Stimulated NF-κB Activity →

Wadhwani SD, Catania A, Lipton JM, et al.

Mechanistic study demonstrating that the α-MSH 10–13 fragment (which includes KPV) directly inhibits TNF-α-stimulated NF-κB activity in vitro. Provides cellular-level confirmation that KPV's anti-inflammatory effect is mediated by NF-κB blockade and is independent of melanocortin receptor binding — a key piece of evidence for KPV's selective action in inflamed tissue.

RecoveryTissue RepairSkin HealthAnti-InflammatoryCombination BlendPreclinical

Related Peptides

BPC-157TB-500GHK-CuKPV

Related Blends

Wolverine StackGLOW

Need to calculate a dose?

Use the Prof. Peptide dosage calculator for accurate reconstitution and dosing math.

Open Calculator

We may earn commissions from peptide vendor affiliate links.

Have a question about KLOW? Send us an email →

For educational and research purposes only. Not medical advice. Not for human use.